A Personalized Plan Is Key to Overcoming Substance Use
Lobeline treatment (5.0 mg/kg dose) significantly reduced ethanol intake tested at all three time points, making the nAChR a promising target of pharmacotherapy development for the treatment of alcohol dependence and relapse (Bell et al., 2009). Farook et al, evaluated…